From this core mechanism Fc engineering has evolved over time into the "engine" of therapeutic antibody development. It ...
Please provide your email address to receive an email when new articles are posted on . Blood dendritic cell antigen 2 and neonatal fragment crystallizable receptor are two novel strategies in lupus ...
Medpage Today on MSN
Myasthenia Gravis Drug Shows Benefits in Wider Range of Patients
Beyond the 4-week mark, both MG-ADL and Quantitative Myasthenia Gravis scores improved in the overall population and in all ...
VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SCOTTSDALE, Ariz. — A novel therapeutic approach ...
On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any biologic Five registrational study readouts expected in ...
This article is based on a poster originally authored by Zachary Fagiani, Rebecca L. Rich, Noah T. Ditto, Larry Yu, Michael Friedman, Glory Gao, Spencer Chiang and Jane Liu from ACROBiosystems..
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback